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The t(8;21) acutemyeloid leukemia (AML)-associated
oncoprotein AML1-ETO disrupts normal hemato-
poietic differentiation. Here, we have investigated
its effects on the transcriptome and epigenome in
t(8,21) patient cells. AML1-ETO binding was found
at promoter regions of active genes with high levels
of histone acetylation but also at distal elements
characterized by low acetylation levels and binding
of the hematopoietic transcription factors LYL1 and
LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1
bind at all AML1-ETO-occupied regulatory regions,
including those of the AML1-ETO gene itself, sug-
gesting their involvement in regulating AML1-ETO
expression levels. While expression of AML1-ETO
in myeloid differentiated induced pluripotent stem
cells (iPSCs) induces leukemic characteristics, over-
expression increases cell death. We find that expres-
sion of wild-type transcription factors RUNX1 and
ERG in AML is required to prevent this oncogene
overexpression. Together our results show that the
interplay of the epigenome and transcription factors
prevents apoptosis in t(8;21) AML cells.
INTRODUCTION
The AML1-ETO (RUNX1-RUNX1T1) oncofusion protein, present
in 10% of all de novo acute myeloid leukemia (AML) cases, is the
result of the translocation t(8;21)(q22;q22), which involves theCell Repor
This is an open access article under the CC BY-NAML1 (RUNX1) gene on chromosome 21 and the ETO gene on
chromosome 8 (Miyoshi et al., 1991). Expression of the AML1-
ETO oncofusion protein in hematopoietic cells results in a
stage-specific arrest of maturation and increased cell survival,
predisposing cells to develop leukemia (Nimer and Moore,
2004). At the molecular level RUNX1 (Runt-related transcription
factor 1; AML1, CBFA2) represents a DNA-binding transcrip-
tional activator factor (Cameron and Neil, 2004; de Bruijn and
Speck, 2004), involved in regulation of hematopoiesis and
myeloid differentiation, while ETO (eight-twenty-one; MTG8,
RUNX1T1) acts as a corepressor by recruiting NCoR/SMRT/
HDAC complexes (Davis et al., 2003; Wang et al., 1998). Apart
from these repressor interactions, the AML1-ETO fusion protein
also assembles into transcription factor complexes. One of
these, consisting of AML1-ETO, CBFB, E proteins HEB and
E2A, LYL1, LDB1, and LMO2, has recently been suggested to
be essential for leukemic maintenance and differentiation block,
as the knockdowns of components of this complex delayed
leukemogenesis in mice (Sun et al., 2013), stressing the impor-
tance of the interplay between the fusion oncogene and other
transcription factors.
Mechanistically, the t(8;21) translocation has long been
thought to convert the RUNX1 transcriptional activator to a
strong repressor by replacing the transactivation domain of
RUNX1/AML1 with an almost complete ETO protein, thereby
inducing a repressive chromatin environment and gene repres-
sion at otherwise activated RUNX1 target sites (Buchi et al.,
2014; Meyers et al., 1995; Okuda et al., 1998; Yergeau et al.,
1997). Nevertheless, a wild-type copy of RUNX1 is still required
to maintain the AML1-ETO leukemic phenotype (Ben-Ami et al.,
2013) as knockdown of RUNX1 in t(8;21) leukemia cell lines re-
sults in cell death (Hyde et al., 2015).ts 17, 2087–2100, November 15, 2016 ª 2016 The Author(s). 2087
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Over the last years, it has become clear that the repressive
nature of AML1-ETO does not define its full biological activities
as the fusion protein has also been reported as an activator of
transcription (Klampfer et al., 1996; Peterson and Zhang, 2004;
Wang et al., 2011). Recent genome-wide studies propose that
relative binding of RUNX1 and AML1-ETO at genes determines
the final transcriptional outcome (Li et al., 2016), while epige-
netically a mechanism for transcriptional activation involving
AML1-ETO and p300 interactions has been suggested (Wang
et al., 2011). Alternatively, it has been suggested that wild-
type RUNX1 interacts with p300, whereas AML1-ETO recruits
HDACs, and binding of RUNX1/p300 and AML1-ETO/HDACs
is mutually exclusive (Ptasinska et al., 2014). Hence, the pre-
cise mechanisms by which AML1-ETO deregulates the
RUNX1 program and the histone acetylation machinery remain
unclear.
So far the majority of studies have been performed using cell
lines with limited validation of findings in clinical samples. In
the present study, we investigated AML1-ETO-associated
epigenetic modification (i.e., functional changes to the genome
that do not involve a change in the DNA) and its relation to
gene expression in patient t(8;21) blasts. We explored the
AML1-ETO complex and the role of the individual components
of this complex in leukemogenesis. We performed genome-
wide binding analysis in cell lines and primary blasts, identifying
two modules of AML1-ETO action, one on promoter regions and
one on enhancer/distal elements. Chromatin immunoprecipita-
tion sequencing (ChIP-seq) studies together with pull-down
and mass spectrometry identified differential as well as similar
co-binding of regulators of transcription and chromatin modifi-
cations in the context of these promoter and distal elements.
Using knockdown assays, we show that a balance between
AML1-ETO, RUNX1, and ERG expression is required for
leukemic maintenance, and that RUNX1 or ERG perturbations
result in AML1-ETO overdose and lethality to cells. Together,
our results suggest that the balanced interplay of the epigenetic
environment and transcription factors retains an anti-apoptotic
phenotype in t(8;21) AML cells.
RESULTS
AML1-ETO Binds Promoter and Distal Genomic
Elements
To investigate the epigenetic alterations associated with AML1-
ETO binding, we used ChIP-seq together with model-based
analysis of ChIP-seq (MACS) peak calling (Zhang et al., 2008)
to identify 2897 common AML1-ETO peaks in cells of three
AML patients with t(8;21) (#186, #12 and #229) (Figure 1A).
Subsequently, we profiled six histone modifications
(H3K4me3, H3K4me1, H3K27ac, H3K36me3, H3K27me3, and
H3K9me3) and accessibility by DNaseI-seq in AML cells of 2
t(8;21) patients expressing the AML1-ETO gene (Figure S1A).
Examining these profiles at the 2897 common AML1-ETO bind-
ing sites revealed two distinct profiles for AML1-ETO that are
differentially marked by H3K4me3, H3K4me1, and H3K27ac
(Figures 1B, 1C, and S1B; Table S1). H3K4me3-enriched
AML1-ETO binding sites constitute promoters of active genes
(Figures 1D and 1E), as is also apparent from the enrichment2088 Cell Reports 17, 2087–2100, November 15, 2016of H3K27ac. In contrast, H3K4me1-enriched regions represent
distal elements and open chromatin regions harboring low
H3K27ac that are associated (by nearest gene approach) with
genes that are lower expressed. Despite low H3K27ac levels,
these distal elements did not enrich for the repressive histone
modifications H3K27me3 or H3K9me3 (Figure 1F), suggesting
that lower gene activity might be related to reduced acetylation
levels.
To investigate whether the difference in chromatin composi-
tion was related to differential transcription factor binding, we
assessed motif enrichment using GimmeMotifs (van Heeringen
and Veenstra, 2011). This analysis revealed enrichment for the
RUNX1 motif in distal elements, while both are enriched for
ETS factor motifs (Figure 1G), in line with previous results
showing enrichment of ETS factor motifs and presence of the
ETS factors ERG and FLI1 at AML1-ETO binding sites in model
cell lines (Martens et al., 2012; Ptasinska et al., 2012).
To examine which functions are affected by the AML1-ETO
fusion product, we assigned promoter and distal-element-asso-
ciated genes to pathways and calculated enrichment (Figure 1H).
This revealed involvement in many signaling pathways,
apoptosis, self-renewal, and other functions related to fully
differentiated myeloid cells. Interestingly, most pathways were
associated with AML1-ETO binding at promoters as well as at
distal elements, suggesting that each pathway receives multiple
AML1-ETO hits.
Identification of theRUNX1/AML1-ETOProtein Complex
To investigate which proteins might be associated with AML1-
ETO binding, we performed pull-down experiments combined
with mass spectrometry analysis. As this assay typically requires
high cell numbers, we used two cell lines, Kasumi-1 and
SKNO-1, which harbor t(8;21) and express AML1-ETO. For
pull-down, we used two oligos, one harboring a RUNX1
consensus motif TGTGGT and a control oligo that contains no
RUNX1 or other common transcription factor motif (Figure 2A).
The RUNX1-containing oligos efficiently pulled down AML1-
ETO in Kasumi-1 cells (Figure 2B), while the control shows
background binding. Subsequently, we analyzed enrichment
for proteins in the RUNX1 oligo pull-down using quantitative
mass spectrometry analysis. This revealed specific enrichments
in both SKNO-1 and Kasumi-1 cells of proteins associated
with the RUNX1-containing oligo, like AML1-ETO, RUNX1, and
CBFB (Figures 2C and S2). To identify proteins that are recog-
nized in both RUNX1 pull-downs, we intersected the enriched
proteins from both pull-downs and identified 34 common pro-
teins that might be involved in regulation at AML1-ETO sites (Fig-
ure 2D; Table S2). Within the common interactors, we identified
FUS, a fusion partner of ERG in AML (Sotoca et al., 2015),
HDAC1 and HDAC2, deacetylases previously suggested as in-
teractors of AML1-ETO (Wang et al., 1998), several splicing
factors as well as LMO2 and LYL1, and two transcription factors
previously identified to interact with AML1-ETO (Sun et al., 2013).
Interestingly, despite enrichment of the motif in AML1-ETO
binding sites (Figure 1G), we did not identify ETS factors in
the pull-down, suggesting these might constitute an indepen-
dent stabilizing factor of the AML1-ETO complex on DNA
(Figure 2E).
Figure 1. Binding Pattern of AML1-ETO in t(8;21) AMLs
(A) Intensity plot showing the AML1-ETO tag densities in AML patient cells with t(8:21) (n = 3) at high confidence AML1-ETO binding sites.
(B) Intensity plot displaying DNaseI accessibility and histone marks at promoter and distal AML1-ETO binding sites in t(8:21) AML #12.
(C) ChIP-seq overview of AML1-ETO binding at the SETD5 promoter and a distal region of PTCH1 in t(8;21) primary AMLs.
(D) Genomic distribution of AML1-ETO binding site locations relative to RefSeq genes. Locations of binding sites are divided in promoter (500 bp to the
transcription start site), exon, intron, and intergenic (everything else).
(E) Expression (reads per kilobase per million reads [RPKM]) of genes associated with AML1-ETO promoter and distal binding sites.
(F) Intensity plot showing active and repressive histone mark enrichment at AML1-ETO binding sites in t(8;21) AML blasts.
(G) Overview of the consensus ETS and RUNX1 motifs found at AML1-ETO binding sites.
(H) Pathway enrichment analysis of genes associated with AML1-ETO binding. Percentage represents the fraction of AML1-ETO-associated genes present in this
pathway. SRP, self-renewal pathway.
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Figure 2. Identification of Interactors of the AML1-ETO/RUNX1 Complex
(A) DNA sequence of oligos used in the pull-down experiment.
(B) Western analysis of identified proteins in the DNA pull-down using the Kasumi-1 cell lysate and AML1-ETO (AE), RUNX1, CBFB, and HDAC1 antibodies.
(C) Scatterplot showing the results of a pull-downmass spectrometry experiment from Kasumi-1 cells. Proteins are plotted by their di-methyl ratios in the forward
(x axis) and reverse (y axis) di-methyl experiment. Specific interactors of the AML1-ETO/RUNX1 pull-down are identified in the lower right quadrant.
(D) Venn diagram showing the overlap of 34 proteins identified as RUNX1 motif interactor in pull-down experiments using Kasumi-1 or SKNO-1 cells.
(E) Schematic diagram showing a hypothetical model of ETS factor stabilization of the AML1-ETO protein complex.Hematopoietic Transcription Factors Bind AML1-ETO-
Occupied Genomic Regions
The identification of LMO2 and LYL1 as interactors of AML1-ETO
(Figure 2D) (Sun et al., 2013) together with the notion that ETS
factor consensus binding sites are enriched at AML1-ETO bind-
ing sites suggested that AML1-ETO is present at sites occupied
by a heptad of proteins previously identified to be crucial for
normal hematopoiesis (Wilson et al., 2010). The genes encoding
these transcription factors are commonly expressed in t(8;21)
but also in other AMLs (Figure 3A) and not mutated in t(8;21)
AMLs (Cancer Genome Atlas Research Network, 2013), sug-
gesting wild-type expression is essential for leukemogenesis.
To investigate whether AML1-ETO binding relates to co-occu-
pancy of this heptad of transcription factors, we performed
ChIP-seq experiments using antibodies recognizing these fac-2090 Cell Reports 17, 2087–2100, November 15, 2016tors in Kasumi-1 t(8;21) cells. We then examined their presence
at the previously identified AML1-ETO binding sites in patients
AML cells. These results revealed that RUNX1, ERG, FLI1, and
TAL1 occupy similar regions as AML1-ETO (Figures 3B and
3C), while GATA2 occupancy was generally low. Co-occupancy
of similar genomic regions by RUNX1 and AML1-ETO and ERG
and AML1-ETO could be confirmed by re-ChIP experiments
(Figure 3D; Martens et al., 2012), suggesting no exclusive
allele-specific binding of these factors. Interestingly, in contrast
to the other heptad factors, LMO2 and LYL1 binding was
enriched at distal elements (Figures 3B and 3C), suggesting
that these might be involved in creating a specific chromatin
environment (as observed in Figure 1B) at these sites.
Indeed, examining gene responses upon LYL1 knockdown
(Sun et al., 2013) revealed that genes associatedwith AML1-ETO
Figure 3. AML1-ETO Co-localizes with Hematopoietic Transcription Factors
(A) Relative expression of hematopoietic transcription factor genes in t(8:21) and other AML subtypes.
(B) Boxplot displaying the tag densities of hematopoietic transcription factors at AML1-ETO binding sites in Kasumi-1 cells. LMO2 and LYL1 are enriched at distal
binding sites.
(C) ChIP-seq of AML1-ETO and other transcription factors in Kasumi-1 cells. Overview of the VPS29 and RAD9B AML1-ETO binding sites showing less binding of
LMO2 and LYL1 at the VPS29 promoter region, whereas increased binding of LMO2 and LYL1 is observed at the HVCN1 distal region.
(D) Re-ChIP experiment validating AML1-ETO and RUNX1 binding to the same locus. Five binding sites were selected and validated for AML1-ETO/RUNX1
binding by re-ChIP using AML1-ETO in the first round of ChIP followed by a second round using RUNX1 and no antibodies. n = 3, mean ± SD.distal element binding are increased in expression while pro-
moter-associated genes are less affected (Table S3).
p300 and HDACs Collaborate with AML1-ETO to
Regulate Local Histone Acetylation
To examine whether promoter and distal element AML1-ETO-
occupied regions have a similar epigenetic pattern in Ka-
sumi-1 cells and patient AML cells, we examined H3 and H4
acetylation at AML1-ETO binding regions in Kasumi-1 cells.
This revealed increased acetylation at AML1-ETO promoter
sites, while in contrast, lower acetylation at distal regions
was observed (Figure 4A), in line with the patient cells (Fig-
ure 1B). We identified the deacetylases HDAC1 and HDAC2as interacting partners of AML1-ETO (Figure 2D), while the
acetyltransferase p300 also has been suggested to interact
with AML1-ETO (Wang et al., 2011). To examine whether dif-
ferential occupancy of these enzymes at promoter or distal
element regions relates to acetylation levels, we performed
ChIP-seq using antibodies against these three proteins. Our
results reveal increased occupancy of p300 and HDACs at
promoter elements but reduced occupancy at distal elements
(Figure 4B). However, within one module the relative occu-
pancy of p300/HDACs is similar (Figure 4B). Re-ChIP experi-
ments revealed the presence of p300/AML1-ETO and
HDACs/AML1-ETO at the same locus (Figures 4C and 4D),
suggesting that AML1-ETO co-localizes with HDAC/p300Cell Reports 17, 2087–2100, November 15, 2016 2091
Figure 4. AML1-ETODistal Binding Regions
Are Hypoacetylated
(A) Heatmap displaying H3K9K14ac and H4ac tag
densities at promoter and distal binding regions of
AML1-ETO (AE). Promoter regions have more
acetylation then distal regions.
(B) Intensity plot showing the tag densities of
H3ac, H4ac, p300, HDAC1, and HDAC2 at
AML1-ETO binding regions. HDACs and p300
are enriched at promoter regions occupied by
AML1-ETO.
(C and D) Re-ChIP experiment validating (C)
AML1-ETO and p300 binding and (D) AML1-ETO
and HDAC1 binding to the same locus. n = 3,
mean ± SD.
(E) Western analysis showing increased H3K9K14
acetylation after HDACi treatment in Kasumi-1
cells, whereas H3K4me3 was unaffected.
(F) Boxplot demonstrating decreased H3K9K14ac
tag densities at AML1-ETO promoter and
increased H3K9K14ac tag densities at distal
binding sites after HDACi treatment in Kasumi-1
cells.
(G) Overview of H3K9K14ac acetylation at AML1-
ETO binding sites showing increased levels at
distal regions and a decrease at the promoter
region of SDF4.
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complexes, whose counteracting activities (HAT/HDAC) might
relate to histone acetylation output.
To see whether this balanced output can be deregulated, we
used MS275 (Entinostat), an HDAC inhibitor that induces cell
death in Kasumi-1 cells (Duque-Afonso et al., 2011; Nebbioso
et al., 2005; Xu et al., 2011). HDACi treatment of Kasumi-1 cells
increased H3K9K14 acetylation, whereas H3K4me3 was unaf-
fected (Figure 4E). Examining histone acetylation at AML1-ETO
binding sites revealed increased acetylation at distal elements,
while at promoter regions a decrease is observed (Figures 4F
and 4G) (Dudakovic et al., 2013; Ooi et al., 2015; Rafehi et al.,
2014). The changes in acetylation level correlate with increased
cell death (Figure S3), suggesting a possible involvement of
AML1-ETO in regulating the apoptosis program, in line with pre-
vious results (Spirin et al., 2014).
t(8;21) AML Addiction to RUNX1 and ERG
Apart from treatment with HDACi, AML1-ETO as well as RUNX1
knockdown have been suggested to induce apoptosis (Ben-Ami
et al., 2013; Spirin et al., 2014). To further explore AML1-ETO
involvement in regulation of the apoptotic pathway, we exam-
ined AML1-ETO binding in patients’ AML cells at genes associ-
ated with apoptotic programming. Using gene names from
KEGG and GO annotation, we identified 172 AML1-ETO binding
regions associated with apoptotic genes (Table S4). In t(8;21)
AML blast cells, these regions were partially enriched for
H3K4me3 and H3K27ac (Figure 5A), representing promoter re-
gions, and partially for H3K4me1 representing distal elements.
As indicated above, promoter regions were related to more
active genes (Figure 5B), while distal-region-associated genes
generally had lower expression. In addition, both promoter and
distal regions were enriched for RUNX1 and ETS motifs and
bound by ERG, as could be corroborated by ChIP-seq in patient
AML cells (Figure 5C). The previously reported dependency on a
copy of WT RUNX1 for AML maintenance in t(8;21) AMLs
together with the lack of mutations for any of the other heptad
factors in t(8;21) AMLs (Cancer Genome Atlas Research
Network, 2013) suggests activity of these transcription factors
is essential for AML1-ETO leukemogenesis. To investigate
whether t(8;21) cells might also be dependent on other transcrip-
tion factors then RUNX1 for their survival, we chose to focus on
ERG, as it was not identified in our RUNX1 proteomic approach
(Figure 2D) but still occupied similar genomic regions as AML1-
ETO (Figure 3B), suggesting it has a DNA-binding-dependent
contribution to the complex. First, we confirmed t(8;21) depen-
dency on RUNX1 by creating a stable inducible RUNX1 knock-
down system in Kasumi-1 cells using a specific short hairpin
RNA (shRNA) targeting the RUNX1 moiety not present in
AML1-ETO (shRUNX1.2) (Figure 5D). Although we only obtained
a RUNX1 knockdown of 50% (Figure 5E), cell-cycle analysis
using propidium iodide (PI) staining demonstrated a marked
increase in the sub-G1 fraction, a hallmark of increased cell
death, and a decrease in live cells (Figures 5F and S4A). This
increased accumulation of dead cells in sub-G1 was due to
apoptosis-mediated cell death as confirmed by Annexin V
staining (Figures 5G and S4B). Next, we created a stable knock-
down system in Kasumi-1 cells using a shRNA targeting ERG.
Similar to RUNX1 knockdown, induction of shRNA expression(Figures 5H and S4C) resulted in increased apoptosis and
decreased cell viability (Figures 5I and S4D–S4G), suggesting
expression of ERG is required for leukemic maintenance and
addiction to this transcription factor in t(8;21) AML.
To investigate which genes are differentially regulated upon
ERG knockdown, we performed RNA-seq using the stable
ERG knockdown system in Kasumi-1. This analysis revealed
an increased expression of CASP8, CASP6, and CASP10 (Fig-
ures 5J and S4H) and decreased expression of BCL2, BIRC7,
and BCL2L1, corroborating that the apoptosis program is acti-
vated upon knockdown of ERG.
AML1-ETO Overdose Increases Cell Death
Increased AML1-ETO expression has been associated with in-
duction of cell death (Burel et al., 2001; Lu et al., 2006). Interest-
ingly, our RNA-seq results revealed that, upon downregulation of
ERG, AML1-ETO expression is increased (Figure S5A). To
confirm this observation, we performed reverse transcription
quantitative polymerase chain reaction (RT-qPCR) using
AML1-ETO-specific primers and western analysis and could
again show increased AML1-ETO expression (Figures 6A and
S5B). To further examine whether increased AML1-ETO expres-
sion correlates with the onset of the apoptosis program, we also
examined expression upon RUNX1 knockdown (using shRNA
RUNX-1.2). This again revealed increased expression of AML1-
ETO by RT-qPCR and western blotting (Figures 6B and 6C).
To investigate whether this increase in AML1-ETO expression
is modulated by altered binding of epigenetic modifiers, we
performed ChIP using p300 and HDAC1 antibodies. ChIP-
qPCR after knockdown of RUNX1 (Figure 6D) or ERG (Fig-
ure S5C) revealed increases in p300 and decreases in HDAC1
occupancy at two promoter regions (RUNX1.P1 and RUNX1.P2)
of AML1-ETO, suggesting that alterations in transcription factor
presence alter epigenetic protein recruitment to the AML1-ETO
promoter resulting in increased transcription.
To confirm the effect of AML1-ETO overexpression on cell
viability, we used a human induced pluripotent stem cell (iPSC)
differentiation system that harbors a dox-inducible AML1-ETO
construct, allowing to express the protein at different stages
during in vitro hematopoietic differentiation. We first tested the
differentiation of iPSCs toward the monocytic and granulocytic
lineages (Figures 6E and S5D) and confirmed granulocytic
differentiation by detecting segmented nuclei and intracellular
granules using May-Grunwald and Giemsa staining (Figure 6F,
top) and confirmed enrichment of CD15 and/or CD16-positive
cells by fluorescence-activated cell sorting (FACS) (Figure S5E).
In contrast, we could not detect any segmented nuclei and gran-
ules after monocytic differentiation (Figure 6F, bottom) but could
observe enrichment for CD14-positive cells (Figure S5F). Using
these iPSC cells and expressing AML1-ETO during granulocytic
differentiation at levels similar to patient blasts (14 ng/mL dox;
Figures 6E and S5G) revealed increased numbers of progenitor
(CD34+) cells in AML1-ETO-expressing conditions, while lower
numbers of granulocytic (CD16-expressing) cells were detected
(Figures 6G and 6H), suggesting a differentiation block along this
lineage. To further assess the oncogenic potential of our differ-
entiation system, we examined at the molecular level whether
AML1-ETO has similar effects on gene expression as in leukemicCell Reports 17, 2087–2100, November 15, 2016 2093
Figure 5. RUNX1 and ERG Are Essential for Kasumi-1 Cells Survival
(A) Heatmap showing H3K4me3, H3K4me1, and H3K27ac tag densities at AML1-ETO binding sites related to genes involved in apoptosis in a t(8:21) AML blast.
(B) Expression (RPKM) of apoptotic genes associated with AML1-ETO promoter or distal binding.
(C) Intensity plot displaying ERG tag density at AML1-ETO (AE) binding sites related to apoptotic genes in t(8:21) patient blast cells (#12).
(D) Schematic diagram showing the shRNA targeting regions for knockdown of either RUNX1 or both RUNX1 and AML1-ETO. *The approximate position of the
shRNA.
(E) RT-qPCR analysis of RUNX1 before and after induction of shRNA for 72 hr targeting RUNX1 in Kasumi-1 cells. Data are normalized to GAPDH and ***p < 0.001.
(F) Cell-cycle analysis by FACS using propidium iodide to measure cellular DNA content in 7 days RUNX1 shRNA control and knockdown cells. Left: cell-cycle
analysis. A representative result is shown from one of the four replicate experiments. Right: bar diagram displaying the distribution of the analyzed cells. Data
represent the mean ± SD values of four independent experiments.
(G) Annexin V staining showing increased apoptosis after KD of RUNX1. n = 3, mean ± SD.
(legend continued on next page)
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cells. For this, we selected five genes that are upregulated and
two that are downregulated upon AML1-ETO knockdown in
AML1-ETO-expressing leukemic cells (Figure S5H, left). This
revealed that in our iPSC system AML1-ETO induction has
similar effects on both gene sets. For example, genes that are
increased in expression upon AML1-ETO knockdown in
leukemic cells (such as CD82 and NFE2) show decreased
expression upon AML1-ETO induction in the iPSC system
(Figure S5H, right). In line with an AML1-ETO oncogene over-
dose-inducing apoptosis in Kasumi-1 cells, overexpression
(60 ng/mL dox) of AML1-ETO in this system resulted in
decreased cell viability (Figures 6E and 6I).
AML1-ETO, RUNX1, and ERG Regulate the Apoptosis
Program in t(8;21) AML
Finally, to investigate the relation between an increase of AML1-
ETO expression and apoptosis, we generated stable cell lines
that allowed double knockdown of RUNX1/AML1-ETO, using
an shRNA construct that targets the common RUNX1 part of
both (shRUNX1.1) (Figure 5D), or ERG/AML1-ETO, using two in-
dependent shRNA constructs. Double knockdown of RUNX1/
AML1-ETO or ERG/AML1-ETO resulted in lower expression of
both targeted proteins (Figures 7A–7D). Interestingly, in both
cases double knockdown rescued the cells from apoptosis
(Figures 7E, 7F, and S6A–S6C), with marked decreases in the
sub-G1 population. These results suggest that ERG and
RUNX1 restrain AML1-ETO from becoming overexpressed and
the subsequent activation of an apoptosis program.
DISCUSSION
Leukemic transformation is associated with the dysregulation of
the normal cell machinery and characterized by alterations in the
epigenome, transcriptome, and proteome. To elucidate the mo-
lecular mechanism(s) of AML1-ETO in leukemogenesis, we
analyzed gene expression and the epigenome of t(8;21) patient
cells and t(8;21) cell lines together with the AML1-ETO/RUNX1
proteome.
We revealed in t(8;21) patient blasts AML1-ETO binding to
both promoter and distal elements and that each type of binding
is associated with specific chromatin characteristics. Promoter
binding sites are high in acetylation and associated with ex-
pressed genes, whereas distal sites are reduced in acetylation
and linked with lowly expressed genes. Interestingly despite
low levels of acetylation, these distal regions are not enriched
for other repressive marks, suggesting lower expression is
mostly related to reduced acetylation. We did not observe differ-
ences in the p300/HDAC balance at promoters and distal re-
gions, although occupancy was generally higher for both p300
and HDACs at promoter regions. These results suggest that
additional factors are involved in regulating the acetylation
output at AML1-ETO binding sites. Using genome-wide binding(H) RT-qPCR analysis of ERG before and after induction of ERG shRNA express
(I) Analysis of cells in sub-G1 after 7 days of ERG shRNA or no induction (cont
A marked increase was observed in sub-G1 cells in comparison to non-induced
(J) Heatmap showing expression changes of apoptosis-associated genes after Eanalysis, we demonstrate that at AML1-ETO promoter binding
sites occupancy of the transcription factors LMO2 and LYL1 is
low, whereas at distal sites increased presence of LMO2 and
LYL1 is observed. It is tempting to speculate that differential
binding of these factors is involved in repressing acetylation at
AML1-ETO distal regions. This would be supported by the
observation that knockdown of AML1-ETO results in decreased
binding of LMO2 and increased the expression of associated
myeloid lineage differentiation genes (Ptasinska et al., 2014).
Our genome-wide analysis also suggests that AML1-ETO and
RUNX1 bind genomic regions occupied by both HDACs and
p300. However, also mutually exclusive binding of RUNX1/
p300 and AML1-ETO/HDACs has been reported (Ptasinska
et al., 2014). Our re-ChIP experiments could show co-occu-
pancy of AML1-ETO/RUNX1 as well as AML1-ETO/p300 and
AML1-ETO/HDACs at similar genomic locations. Although these
findings would be in line with other studies suggesting AML1-
ETO/RUNX1 (Li et al., 2016) and AML1-ETO/p300 co-occupancy
at single loci (Wang et al., 2011), here, as well as in the other
studies, only a limited number of regions were included in the
re-ChIP experiment and no genome-wide re-ChIP analysis was
performed.
To better understand the activating and repressive nature of
AML1-ETO at protein-DNA level, we performed, in addition to
ChIP-seq analysis, DNA pull-downs using t(8;21) cell lysates
and RUNX1-motif-containing oligos. Apart from previously iden-
tified AML1-ETO interactors such as the transcription factors
LYL1 and LMO2 and the deacetylases HDAC1 and HDAC2, we
also identified several proteins involved in RNA splicing (for
example, several RBMs and SRSFs), suggesting that the
RNA-processing machinery is directly linked to the transcription
regulation machinery and deregulated by AML1-ETO. Interest-
ingly, recent mutational analysis in a large cohort of AMLs
identified splicing factors as commonly mutated in AMLs (Can-
cer Genome Atlas Research Network, 2013), suggesting dereg-
ulation of this machinery might be a general feature of AMLs and
also involved in t(8;21) leukemogenesis.
Motif analysis of the patient blasts’ AML1-ETO binding regions
revealed the presence of ETSmotifs, in line with reports that ETS
factors are involved in AML1-ETO leukemogenesis (Martens
et al., 2012; Trombly et al., 2015). Interestingly, we did not find
ETS factors in our RUNX1 motif pull-down analysis suggesting
protein-protein interaction is not sufficient to interact with the
RUNX1 or AML1-ETO complex, but the additional presence of
a DNA consensus binding site is required in order to stabilize
interaction with these complexes.
An ETS factor of particular interest is ERG, as it is required for
definitive hematopoiesis and self-renewal of hematopoietic stem
cells (Loughran et al., 2008; Ng et al., 2011) and showed co-oc-
cupancy with AML1-ETO at all binding sites in t(8;21) cell lines
and blasts. Moreover, so far no mutation has been reported for
ERG in t(8;21) leukemogenesis, underscoring that its activityion for 72 hr in Kasumi-1 cells. Data are normalized to GAPDH ***p < 0.001.
rol). Data represent the mean ± SD values of four independent experiments.
cells.
RG knockdown.
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might be essential for AML1-ETO leukemogenesis. Interestingly,
upon knockdown of ERG in t(8;21) cells, we observed an in-
crease in sub-G1 cells, indicative of apoptosis onset. In addition,
we could corroborate previous reports that upon RUNX1 knock-
down a similar phenotype was observed (Ben-Ami et al., 2013)
and that a delicate balance of RUNX1 and AML1-ETO is
essential for leukemic maintenance of Kasumi-1 cells. Perturba-
tion of this equilibrium by depletion of AML1-ETO leads to loss
of self-renewal, whereas knockdown of RUNX1 results in
apoptotic cell death (Ben-Ami et al., 2013; Spirin et al., 2014).
Here, our ERG knockdown results suggest that apart from
RUNX1 and AML1-ETO, t(8;21) cells are also dependent on
ERG expression and as such, in addition to RUNX1, are also
ERG addicted.
We confirmed the dependency on AML1-ETO/RUNX1 bal-
ance by generating a stable inducible RUNX1 knockdown
system in Kasumi-1 cells and suggest that increased expression
of AML1-ETOmight be linked to the induced apoptosis program.
The present study demonstrates that not only knockdown of
RUNX1, but also knockdown of ERG upregulates AML1-ETO
expression and thus interferes with the AML1-ETO/RUNX1 equi-
librium, possibly resulting in more AML-ETO binding to RUNX1
target genes or redistribution of AML1-ETO binding as sug-
gested previously (Ptasinska et al., 2014).
Using an iPSCsmodel system, we verified that overexpression
of AML1-ETO induces cell death, suggesting that only a specific
dose of AML1-ETO relates to leukemogenesis, corroborating
previous findings (Pabst et al., 2001; Tonks et al., 2004). In
addition, the link between oncogene overdose, i.e., higher
expression of AML1-ETO, and increased apoptosis, corrobo-
rates previous studies of inherent pro-apoptotic activities of
AML1-ETO (Lu et al., 2006) and an anti-apoptotic role for
RUNX1 (Ben-Ami et al., 2013). Oncogene overdose is a relatively
new concept highlighted in particular by recent studies of
mutant-BRAF in melanoma and the fusion kinase nucleophos-
min–anaplastic lymphoma kinase (NPM-ALK) in anaplastic large
cell lymphoma (Amin et al., 2015). To our knowledge, this
concept, which is based on mutated kinases, has not been re-
ported for AML-associated oncogenes nor extended to mutated
transcription factors.
Importantly, we could show that double knockdown of either
RUNX1 and AML1-ETO or ERG and AML1-ETO rescues the cellsFigure 6. AML1-ETO Oncogene Expression Level Determines the Fate
(A) RT-qPCR analysis of AML1-ETO and ERG in Kasumi-1 cells, before and after i
after ERG KD. Data are normalized to GAPDH ***p < 0.001.
(B and C) RT-qPCR (B) and western (C) analysis show increased AML1-ETO (AE
(D) p300 and HDAC ChIP qPCR before and after induction of RUNX1 shRNA for 7
data were normalized with H2B. n = 3, mean ± SD.
(E) Effect of dox concentration on AML1-ETO expression during granulocytic d
protocol toward granulocytes. Bottom: RT-qPCR analysis of AML1-ETO expressio
normalized to GAPDH.
(F) Cytospin of iPS cells differentiated toward granulocytic and monocytic cells us
Bottom: monocyte differentiated cells.
(G) Flow cytometry results of iPSC differentiation toward granulocytes with (14 n
expressing cells after normal in vitro differentiation (left) or in the presence of AM
(H) Bar diagram showing the percentage of CD34 and CD16 cells in AML1-ETO-
(I) Effect of increased AML1-ETO expression (using increased concentrations of
viability was checked by trypan blue cell counting. n = 3, mean ± SD.from apoptosis, further illustrating the critical role of increased
AML1-ETO expression in apoptosis induction and the impor-
tance of a finely tuned AML1-ETO/RUNX1 and AML1-ETO/
ERG expression equilibrium. Corroborating these results are
previous observations in SKNO-1 cells selected for stable
continuous ERG knockdown in which reduced AML1-ETO
expression (as compared to wild-type SKNO-1 cells) was
observed (Martens et al., 2012), which suggested that only
subclones that in addition to reduced ERG also harbored low
AML1-ETO could survive selection.
Together these results show that a delicate balance of AML1-
ETO, RUNX1, and ERG expression is required for leukemic
maintenance. Altering this balance might be used as a therapeu-
tic entry point to induce apoptosis in t(8;21) cells.
EXPERIMENTAL PROCEDURES
Cell Culture
Kasumi-1 (Asou et al., 1991) was routinely cultured in RPMI-1640 supple-
mented with 10% fetal calf serum (FCS) and 1% pen/strep at 37C.
Kasumi-1 shRNA stable cell lines were cultured in tet-free FBS, and shRNA
expression was induced for 72 hr for RT-qPCR and 7 days for cell-cycle
analysis by adding 600 ng/mL doxycycline. iPSCs cells were generated
from megakaryoblast at the Sanquin Research Department of Hematopoie-
sis, Amsterdam, the Netherlands. Briefly peripheral blood mononuclear cells
(PBMCs) were isolated using density gradient centrifugation using Ficoll, and
then CD34+ cells were isolated using CD34 beads. CD34+ were initially
cultured in CD34 expansion media (Stemspan, 100 mg/SCF, 1 mg/mL inter-
leukin-3 [IL-3], 1 mg/mL IL-6, 1 U/mL TPO, and L4646) for 5 days, and
then media was changed to Stemspan medium supplemented with
100 mg/mL SCF, 10 U/mL TPO, and 1 mg/mL IL-1B. On the ninth day,
CD34/CD41 cells were sorted and used for iPSCs generation. iPSCs were
routinely cultured in E8 Media (Life Technologies).
AML1-ETO-expressing iPSCs cell were generated by using a previously
described strategy of knockin using an AAVS1 homology donor vector and
CRISPR-Cas9 (Mali et al., 2013). Briefly two million iPSCs were nucleofected
with donor vector containing an inducible promoter for expression of the
cloned gene (Qian et al., 2014) and a gene targeting vector for the AAVS1 locus
(Mali et al., 2013). Transfected cells were plated in one well of a vitronectin
(Life Technologies)-coated 6-well plate in E8 media (Life Technologies) supp-
lemented with 10 mM of rock inhibitor for 24 hr. Cells were dissociated using
accutase (Life Technologies) and seeded at low density on a vitronectin-
coated dish in E8 media together with 0.25 mg/mL puromyocin. Cells were
selected for puromyocin for 14 days, and positive clones were selected by
PCR. AML1-ETO iPSCs were routinely maintained in E8 media (Life Technol-
ogies) on vitronectin-coated plates. iPSCs generation was performed byof Leukemic Cells
nduction of a shRNA targeting ERG for 72 hr. AML1-ETO expression increased
) expression after RUNX1 KD for 72 hr in Kasumi-1.
2 hr. Two primers were used targeting the promoter of RUNX1/AML1-ETO, and
ifferentiation of iPSCs. Top: schematic representation of iPSC differentiation
n during granulocytic differentiation using different dox concentration; data are
ing May-Grunwald and Giemsa staining. Top: granulocyte differentiated cells.
g/mL dox) or without (no dox) AML1-ETO expression examining CD34/CD31-
L1-ETO expression (right).
expressing (+dox 14 ng/mL) and control cells (no dox).
dox) on viability of iPSCs differentiated along the granulocytic pathway. Cell
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Figure 7. Double Knockdown of AML1-ETO and ERG or AML1-ETO and RUNX1 Rescues Cells from Apoptosis
(A and B) Analysis of double KD of AML1-ETO and RUNX1 by (A) RT-qPCR (***p < 0.001) and (B) western analysis.
(C and D) Double KD of AML1-ETO and ERG is confirmed by (C) RT-qPCR (***p < 0.001) and (D) western analysis.
(E and F) Histograms showing the percentage of sub-G1 cells after (E) AML1-ETO (AE) and RUNX1 or (F) AML1-ETO (AE) and ERG double KD. Data represent the
mean ± SD values of four independent experiments.Sanquin, Amsterdam. t(8;21) AML blasts from peripheral blood or bone
marrow were obtained and processed as previously described (Martens
et al., 2012).
Granulocytic and Monocytic Differentiation
For granulocytic and monocytic differentiation, AML1-ETO iPSCs were
dissociated using accutase and resuspended in E8 media supplemented
with rock inhibitor (10 mg/mL). Cells were seeded at a density on Geltrex
(Life Technologies)-coated 6-well plate, so that only four to five colonies
emerge in each well. Cells were maintained in E8 media until individual
colonies grew up to approximately 500 mm in diameter. E8 media was then
replaced by stemline media supplemented with 1% penstrep, 1:100 insulin-
transferrin-selenium-Ethanolamine (ITS), and cytokines (20 ng/mL BMP4,
40 ng/mL VEGF, and 5 ng/mL bFGF). This day was considered as day 0 of
differentiation, and the medium was refreshed after 3 days. On day 6, the
cytokines were again replaced with a specific cytokine cocktail for monocyte
(50 ng/mL SCF, 50 ng/mL FLT3, 50 ng/mL IL-3, 50 ng/mL M-CSF, and
10 ng/mL TPO) (Niwa et al., 2011) or neutrophil differentiation (50 ng/mL2098 Cell Reports 17, 2087–2100, November 15, 2016SCF, 50 ng/mL IL-3, 50 ng/mL G-CSF, and 5 ng/mL TPO) (Morishima et al.,
2014), and thereafter medium was changed every 3–4 days. The overall
scheme of differentiation is outlined in Figure S5D. Dox (14 ng/mL) was added
on the sixth day of differentiation, and cells were kept continuously in dox until
analyzed by flow analysis.
ChIP and ChIP-Seq
Chromatin from cell lines was harvested as described (Mandoli et al., 2014).
ChIPs were performed using specific antibodies to AML1-ETO (Diagenode,
C15310197), RUNX1 (Abcam; ab23980), ERG (Santa Cruz Biotechnology;
sc-353), FLI1 (Santa Cruz; sc-356), GATA2 (Santa Cruz; sc-9008), HEB
(Santa Cruz; sc-357), and LYL1 (Santa Cruz; sc-374164) and analyzed by
quantitative PCR or sequencing analysis. Relative occupancy was calculated
as fold over background, for which the second exon of the Myoglobin gene
or the promoter of the H2B gene was used. Chromatin isolation and
ChIP-seq from primary t(8;21) AMLs was done according to Blueprint pro-
tocols (www.blueprint-epigenome.eu/index.cfm?p=7BF8A4B6-F4FE-861A-
2AD57A08D63D0B58) using Diagenode antibodies.
Illumina High-Throughput Sequencing
ChIP-seq libraries for transcription factors were prepared from precipitated
DNA of 5million cells (four to five pooled biological replicas) using the Kapa hy-
perprep kit. For RNA-seq, 250 ng of RNA was used for ribozero (Illumina
MRZ11124) and subsequent library preparation. Libraries were loaded on
E-gel and a band corresponding to 300 bp (DNA + Adaptor) was collected
and used for cluster generation on the Illumina HiSeq genome analyzer. The
42- to 50-bp tags were mapped to the reference human genome hg19 using
the Burrows-Wheeler Alignment Tool (BWA). For each base pair in the
genome, the number of overlapping sequence reads was determined, aver-
aged over a 10-bp window and visualized in the UCSC genome browser
(http://genome.ucsc.edu). All ChIP-seq and RNA-seq data can be down-
loaded from the Gene Expression Omnibus (GSE76464 and GSE23730), or
the Blueprint DCC (http://dcc.blueprint-epigenome.eu/#/files), and the bio-
informatic analysis of the data is described in the Supplemental Information.
Pull-Down, Dimethyl Labeling, and Liquid Chromatography Mass
Spectrometry Analysis
Nuclear extract preparation and pull-downwere performed as described in Sup-
plemental Experimental Procedures. Forward and reverse pull-down proteins
were labeled by dimethyl isotopes (Boersema et al., 2009) mixed and measured
byQExactivemass spectrometer (ThermoFisherScientific). Rawdatawerepro-
cessed by MaxQuant software, and plots were generated using Perseus.
ACCESSION NUMBERS
The accession numbers for the data reported in this paper are GEO:
GSE76464 and GSE23730. Data can also be obtained from the Blueprint
DCC (http://dcc.blueprint-epigenome.eu/#/files).
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